title: Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.
abstract: Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver disease in the USA with a growing prevalence worldwide. Nonalcoholic steatohepatitis (NASH), progressive form of NAFLD, can lead to the development of cirrhosis, hepatocellular carcinoma, and the need for liver transplantation. Treatment of NASH may decrease the risk of progressive disease. Treatment for NAFLD should center around weight loss and exercise. Pharmacotherapy with vitamin E and pioglitazone should be considered for those with NASH, especially those with fibrosis. Weight loss surgery is also an effective treatment for NASH in individuals with other indications for surgery. In this review, we will discuss the currently available therapies for NASH including lifestyle, pharmacologic, and surgical options.
authors.affiliation: Gastrointestinal Unit, Liver Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. kcorey@partners.org.|Department of Gastroenterology and Hepatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. kcorey@partners.org.
authors.forename: Kathleen E
authors.identifier: http://orcid.org/0000-0003-2882-7264
authors.initials: KE
authors.lastname: Corey
authors.affiliation: Gastrointestinal Unit, Liver Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.|Department of Gastroenterology and Hepatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
authors.forename: Mary E
authors.initials: ME
authors.lastname: Rinella
mesh_terms: D000975:Antioxidants / Q000627:therapeutic use; D050110:Bariatric Surgery; D015444:Exercise; D043371:Fatty Acids, Omega-6 / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D065626:Non-alcoholic Fatty Liver Disease / Q000188:drug therapy* / Q000601:surgery*; D010431:Pentoxifylline / Q000627:therapeutic use; D000077205:Pioglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use*; D014810:Vitamin E / Q000627:therapeutic use
chemical_list: D000975:Antioxidants; D043371:Fatty Acids, Omega-6; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D014810:Vitamin E; D010431:Pentoxifylline; D000077205:Pioglitazone
keywords: Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Pioglitazone; Vitamin E; Weight loss surgery